上海心玮医疗科技股份有限公司（06609.HK）于6月29日宣布，其董事会已批准一项H股回购计划。根据该计划，公司拟动用不超过1亿港元的资金，在公开市场上回购不超过100万股H股。
此项回购计划旨在优化公司资本结构，提升每股收益，并彰显管理层对公司未来长期发展前景的信心。市场分析认为，此举有助于向投资者传递积极信号，并可能对股价形成支撑。
上海心玮医疗科技股份有限公司（06609.HK）于6月29日宣布，其董事会已批准一项H股回购计划。根据该计划，公司拟动用不超过1亿港元的资金，在公开市场上回购不超过100万股H股。
此项回购计划旨在优化公司资本结构，提升每股收益，并彰显管理层对公司未来长期发展前景的信心。市场分析认为，此举有助于向投资者传递积极信号，并可能对股价形成支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.